Volition Announces Clinical Research Study with Oncovet
HENDERSON, Nev., November 14, 2022 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multinational epigenetics company, announced a clinical research study with Oncovet, a renowned veterinary referral clinic specializing in medical and radiation oncology.
The non-interventional study is led by Dr. Jerome Benoit, Clinical Director of Oncovet, and will assess circulating nucleosomes from dogs and cats with cancer using Volition’s Nu.Q® Vet Cancer assay.
Volition’s Nu.Q® Veterinary Cancer Screening Test is a simple, easy-to-use blood test currently available for cancer screening in dogs with ongoing research into its use for cancer screening in cats and the disease surveillance in both species.
Dr. Jérôme Benoit, Clinical Director at Oncovet, said: “Volition’s Nu.Q® Vet Cancer Test has already been shown to detect systemic cancers in dogs, such as lymphoma and hemangiosarcoma. We will investigate whether other common cancers that we regularly see in the clinic could also be detected in dogs and cats by measuring circulating nucleosomes at diagnosis and throughout treatment.
“We are excited to be working with the Volition team, providing samples from 100 dogs and 25 cats with a wide range of cancers, over the coming year. We look forward to supporting Volition as the company expands its operations in Europeenabling veterinarians and pet owners across the region to benefit from the Nu.Q® Vet Cancer test. »
dr. Tom ButeraCEO of Volition Veterinary Diagnostics Development LLC, said, “We are delighted to be collaborating with Dr. Benoit and his team on this research study. Jérôme is highly respected in the veterinary oncology industry and Oncovet is well known in Europe for the design and management of veterinary clinical trials in dogs and cats.”
“We hope that this initial study will be the start of an effective and long-term relationship with Oncovet, as we seek to expand the range of cancers that our Nu.Q® Vet Cancer test can detect across different species. We look forward to sharing the results.”
Volition develops simple, easy-to-use and cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including cancer in humans and animals. For more information on Volition’s Nu.Q® technology, visit: www.volition.com.
Note to editors:
The results of a clinical study conducted by Volition and Professor Wilson-Robles and the team at Texas A&M Universitypeer reviewed and published in August 2022showed that:
Volition is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use and cost-effective blood tests to help diagnose and monitor a range of life-changing diseases, including including certain cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and follow-up have the potential not only to prolong patients’ lives but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids – an indication that disease is present.
Volition’s research and development activities are centered on Belgiumwith an innovation lab and office in the United States and additional offices in London and Singapore.
The contents of Volition’s and Oncovet’s web site addresses are not incorporated by reference into this document and should not be considered part of this document. These web site addresses are included herein as inactive textual references only.
Oncovet’s mission is to offer the best reception and treatment possible to the patients you entrust to us. Oncovet aims for excellence and relies on the skills of its specialists recognized at European level, as well as on the team that accompanies them, to offer comprehensive care. Our services include surgery, cardiology, imaging, radiation therapy, medical oncology and internal medicine. We care for patients who come to us from everywhere Europe. For more information, visit: www.oncovet.fr
Louise Batchelor/Debra DaglichWill, [email protected] +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which relate to matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expect”, “anticipate”, “intend”, “plan”, “aim”, “target”, “believe”, “seek”, “estimate”, “optimize” , “potential”, “objective”, “suggests”, “could”, “will”, “should”, “may”, “will”, and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other things, Volition’s expectations regarding the potential uses, benefits and efficacy of its Nucleosomics™ technology platform, including the Nu.Q® Vet Cancer test, as well as the anticipated benefits of its relationship with Oncovet. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, the results of studies testing the effectiveness of its tests, market failure to accept Nu.Q® Vet from Volition Cancer Test or other products based on its Nucleosomics™ platform; Volition’s failure to provide adequate intellectual property protection; Volition’s inability to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition will face fierce competition and its Covered Products may become obsolete due to the highly competitive nature of the diagnostic and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents Volition files with the Securities and Exchange Commission. For example, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Forward-looking statements are based on current expectations, estimates and projections about Volition’s business, based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release and, except as required by law, Volition does not undertake to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its affiliates. All other trademarks, service marks and trade names mentioned in this press release are the property of their respective owners.